Immunic AG

Multiple Sclerosis Therapeutics

Immunic AG’s clinical research is centered on multiple sclerosis, with active studies in relapsing multiple sclerosis and relapsing-remitting multiple sclerosis. The programme includes evaluation of disease activity, relapse prevention, and neurological outcomes in adults with active disease.

  • Relapsing multiple sclerosis
  • Relapsing-remitting multiple sclerosis
  • Disease activity assessment

Clinical interest in this area includes treatment of inflammatory disease activity and control of relapse-related progression.

Progressive Multiple Sclerosis

The sponsor also studies progressive forms of multiple sclerosis, with attention to measures of neurodegeneration and structural change in the brain. This area reflects a focus on the unmet therapeutic needs of patients with worsening disability.

  • Progressive multiple sclerosis
  • Brain atrophy
  • Neurodegeneration

Research in this field includes clinical evaluation of outcomes linked to structural preservation and long-term neurological function.

Magnetic Resonance Imaging and Disease Monitoring

Several trials use magnetic resonance imaging to examine inflammatory and structural markers of multiple sclerosis. Imaging-based endpoints are used to characterize lesion burden, brain volume loss, and overall disease activity.

  • MRI-based disease assessment
  • Whole brain atrophy
  • Structural imaging biomarkers

This area supports clinical interest in objective monitoring of central nervous system disease processes.

Drug Interaction and Pharmacokinetics

Immunic AG also funds studies on the pharmacokinetics and drug-drug interaction profile of IMU-838, including interactions relevant to co-administered therapies and common concomitant medications. These studies support the therapeutic development of the compound in multiple sclerosis populations.

  • Pharmacokinetic profiling
  • Drug-drug interaction studies
  • Concomitant medication considerations

Research in this area includes evaluation of absorption, elimination, and compatibility with other treatments used in clinical practice.

Want to learn more about this study or check if you can participate? Contact us.

Matched clinical trials

  • Study on the Effects of IMU-838 (Vidofludimus Calcium) for Patients with Relapsing-Remitting Multiple Sclerosis

    Recruiting

    Investigated drugs:
    Bulgaria Germany Poland Romania
  • Study on the Effects of Vidofludimus Calcium (IMU-838) in Patients with Progressive Multiple Sclerosis

    Recruiting

    Investigated diseases:
    Investigated drugs:
    Bulgaria Czechia Germany The Netherlands Poland Romania
  • Study on the Effects of Vidofludimus Calcium in Adults with Relapsing Multiple Sclerosis

    Not recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    Estonia Germany Poland Romania